LETTER TO EDITOR



The overlap between Alzheimer's disease and epilepsy uncovered by transcriptome sequencing

Dear editor,

We conducted a combinated analysis of the hippocampal transcriptome of Alzheimer's disease (AD) and epilepsy mice for the first time. Our study found that TNF- α -HIF-1-NF- κ B pathway axis and circadian rhythm pathway are involved in the pathogenesis of AD and epilepsy. Most importantly, *FZD7* is remarkable upregulated in the hippocampus of APP/PS1 mice and the temporal cortex of humans, which suggests that *FZD7* maybe an important target in the early pathological process of AD.

It is believed that AD and epilepsy are two distinct neurological diseases based on its main symptoms. More and more clinical data show that there is interaction between AD and epilepsy.¹ According to a retrospective study of medical records of new-onset unexplained epilepsy and myoclonus, the incidence rate of epilepsy is 13.4% for lateonset AD patients (n = 1320).² In addition, In a 4-year follow-up study in Taiwan, 4.7% of the 20 000 AD patients showed seizure symptoms.³ These are only clinical data, and the number of subclinical epilepsy-like symptoms may be higher.

It is recognized that Down syndrome (DS) may be accompanied by seizures, and DS patients have typical neuropathological changes in AD,⁴ which further illustrates the overlap between epilepsy and AD in pathology. Although there are clinical and pathological commonality between epilepsy and AD, it is still unclear how and why epilepsy is associated with an increase in AD pathology. Our previous research found that the circadian rhythms pathway was significantly down-regulated in the hippocampal CA3 region of AD and epilepsy patient.⁵ In this study, we attempt to investigate the core pathways and genes of epilepsy and AD.

We analyzed the differentially expressed genes (DEGs) in APP/PS1 transgenic mice (n = 3) and pentylenetetrazole (PTZ) kindled epileptiform mice (n = 3) versus C57B6/J mice (WT mice, n = 3) by transcriptome sequencing. As shown in Figure 1A, the volcano map showed a total of 2184

DEGs were identified from APP/PS1 mice compared with WT mice, with 1293 genes were upregulated. Meanwhile, 2574 DEGs were identified from epileptiform mice with 1447 genes were upregulated. The relationship between the three groups of DEGs was intuitively shown by the Wayne diagram (Figure S1A). DEGs clustering analysis illustrated that the proportion of AD upregulated genes was more than that of epilepsy mice (Figure S1B).

Figure 1C showed that the most enriched upregulated GO terms in AD mice were cell adhesion, biological adhesin, intracellular signal transduction, immune system process, and immune response. While, cellular metabolic process and metabolic process were the most enriched upregulated GO terms in epileptic mice (Figure 1D). In order to determine the signal transduction pathways involved in DEGs,⁶ we conducted KEGG analysis. Figure 1E illustrated that phagosome (corrected P = 0.0014) and antigen processing and presentation (corrected P = 0.0014) pathways were significant up-regulated in APP/PS1 mice. The circadian rhythm pathway was downregulated in epileptic mice (Figure 1F), which verified our previous research.⁵

In order to analyze protein protein interaction (PPI), we input two sets of DEGs into NetworkAnalyst 3.0,⁷ and the results are similar to KEGG analysis (Figure 1G,H). See the Supporting Information Materials for details. Through the analysis of the pathway, we found that Alzheimer's disease pathway was significantly enriched in both AD and epileptic mice (Figure S2A). Next, we further analyzed the enrichment pathway of AD and epileptic mice with GSEA. In GSEA analysis, 26 gene sets were significant at FDR < 25% in epileptic mice. We were surprised to find the gene set, Nagashima_ NRG1_ SIGNALING_ Up, was the most significant enriched phenotype in epileptic mice, its NES = 2.16, FDR q-val = 0 (Figure 11). Neuregulin-1 (NRG1) is a member of neurotrophic factors in the central nervous system (CNS). It is closely related to normal physiological functions such as neuronal growth, migration and differentiation, and synaptic plasticity via activating

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

^{© 2020} The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics



FIGURE 1 Analysis of physiological function signal pathway of DEGs. Volcano plot of the DEGs in APP/PS1 mice (A) and epileptiform mice (B). GO enrichment of DEGs in APP/PS1 mice (C) and epileptiform mice (D). KEGG pathways enrichment in APP/PS1 mice (E) and epileptiform mice (F). PPI pathway network analysis in APP/PS1 mice (G) and epileptiform mice (H). I, Enrichment plot of Nagashima_NRG1_SIGNALING_Up in epileptiform mice by GSEA analysis

ErbBs receptors.⁸ NRG1 is also important for the translation of dopaminergic, glutamatergic, and GABAergic neurotransmitters.⁹ Our results suggest that NRG1 pathway may be a bridge between AD and epilepsy. In addition, Figure S2B showed that PHONG_TNF_TARGETS_UP was enriched in epileptiform mice with NES = 1.92, FDR *q*-val = 0.05. Combined with the analysis results of HIF and NF- κ B pathway enriched in previous PPI analysis, it shows that TNF- α -HIF-1-NF- κ B pathway axis should be focused on in the pharmacological intervention mechanism of epilepsy and AD. As illustrated in Figure 2A,B, PPI analysis of AD and epileptic mice mainly focus on neurodegenerative diseases pathways. As there are few common differential genes, we input these genes into the human AD database (Alzdata)¹⁰ to investigate their expression levels in human samples. We unexpectedly found that the expression of *FZD7* in the temporal cortex of AD patients was extremely upregulated than that of healthy people (P = 0.00017). Moreover, *FZD7* level was also significantly higher in entorhinal cortex than that of healthy people (P = 0.012; Figure 2C). Using brain single cell sequencing data in public databases (GSE67835),



FIGURE 2 Functional analysis of core genes of AD and epilepsy. A, PPI gene network of APP/PS1 mice and epilepsy mice. B, PPI pathway network of APP/PS1 mice and epilepsy mice. C, *FZD7* level in human sample. D, The distribution of *FZD7* in brain single cell sequencing data (GSE67835). E, Gene regulatory network of *FZD7*. F, Research route and the mechanism summary of FZD7

we found that FZD7 is mainly distributed in astrocytes and neurons (Figure 2D). In the single gene analysis of FZD7, we conducted a network analysis of FZD7's PPI, acting genes, related lncRNA, target miRNA, and indirectly acting genes (Figure 2E). Figure 2F is the research route of this study and the mechanism summary of FZD7. As a Gprotein coupled receptors, there are few studies on FZD7 that mainly focusing on cancer at present. In this study, we found for the first time that FZD7 is remarkable upregulated in temporal cortex in AD patients. As an important part of cognition, temporal cortex is very vulnerable to attacks in the early stages of AD. These results suggest that the inhibition of *FZD7* in the early stages may prevent the progression of AD pathology and further systematic biological experiments are needed to verify it.

DATA AVAILABILITY STATEMENT

The data that support the findings of the current study are available from the corresponding author on reasonable request.

AUTHOR CONTRIBUTIONS

Qingchun Zhao and Fuhai Hui designed and supervised this study. Xiaowen Jiang performed experiments and

bioinformatics analysis. Hongyuan Lu collected data and ran the analyses. Wenwu Liu, Zhongchan Wu, Qiong Wu, Xiang Li, and Zihua Xu discussed and commented on the manuscript.

ACKNOWLEDGMENTS

We would like to thank the National Natural Science Foundation of China (numbers 81673328 and 81973209) for funding this study.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All animal experiments were carried out in accordance with the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). This study was approved by the Ethics Committee of the Institutional Animal Care and Use Committee of Shenyang Pharmaceutical University.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

Xiaowen Jiang¹ Hongyuan Lu² Wenwu Liu¹ Zhongchan Wu¹ Qiong Wu¹ Xiang Li¹ Zihua Xu¹ Fuhai Hui¹ Qingchun Zhao^{1,3} (**b**)

 ¹ Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, P. R. China
² Department of Clinical Pharmacology, China Medical University, Shenyang, P. R. China
³ Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, P. R. China

Correspondence

Qingchun Zhao, Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China. Email: zhaoqingchun1967@163.com Fuhai Hui, Department of ClinicalPharmacy, Shenyang Pharmaceutical University, Shenyang 110016, P. R. China.∩ Email: huifuhai@163.com

ORCID

Qingchun Zhao https://orcid.org/0000-0001-9256-9971

REFERENCES

- Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer's disease: causes and clinical relevance. *The Lancet Neurology*. 2017;16(4):311-322.
- Beagle AJ, Darwish SM, Ranasinghe KG, La AL, Karageorgiou E, Vossel KA. Relative incidence of seizures and myoclonus in Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia. *J Alzheimers Dis.* 2017;60(1):211-223.
- 3. Cheng CH, Liu CJ, Ou SM, et al. Incidence and risk of seizures in Alzheimer's disease: a nationwide population-based cohort study. *Epilepsy Res.* 2015;115:63-66.
- Veall RM. The prevalance of epilepsy among mongols related to age. J Mental Deficiency Res. 1974;18(2):99-106.
- Jiang XW, Lu HY, Xu Z, et al. In silico analyses for key genes and molecular genetic mechanism in epilepsy and Alzheimer's disease. *CNS Neurol Disord Drug Targets*. 2018;17(8):608-617.
- 6. Wang G, Yu J, Yang Y, et al. Whole-transcriptome sequencing uncovers core regulatory modules and gene signatures of human fetal growth restriction. *Clin Transl Med.* 2020;9(1):9.
- Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. *Nucleic Acids Res.* 2019;47(W1):W234-w241.
- Jiang Q, Chen S, Hu C, Huang P, Shen H, Zhao W. Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. *Mol Med Rep.* 2016;14(3):2614-2624.
- Ledonne A, Nobili A, Latagliata EC, et al. Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons. *Mol Psychiatry*. 2015;20(8):959-973.
- Zhang DF, Fan Y, Xu M, et al. Complement C7 is a novel risk gene for Alzheimer's disease in Han Chinese. *Natl Sci Rev.* 2019;6(2):257-274.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.